Search Results

The approval of Revtorpyk (gedatolisib) gives Celcuity a new treatment option for HR-positive, HER2-negative breast cancer patients without PIK3CA mutations, following positive Phase III VIKTORIA-1 data showing improved progression-free survival. Celcuity has received approval from the US Food and Drug Administration (FDA) for Revtorpyk (gedatolisib), a targeted therapy designed to inhibit the PI3K/AKT/mTOR (PAM) signalling pathway in certain patients with advanced breast cancer. The therapy has been approved in combination with fulvestrant, with or without Pfizer’s Ibrance (palbociclib), for adults with: Hormone receptor-positive (HR-positive) HER2-negative Locally advanced or metastatic breast cancer Second-line or later disease No PIK3CA mutation The approval represents a new treatment approach for a subset of breast cancer patients who have historically had limited targeted therapy options. Following the regulatory decision, Celcuity shares initially increased by approximately 7% before giving back most gains in after-hours trading. How Revtorpyk Works in Breast Cancer Revtorpyk is an intravenously administered comprehensive inhibitor of the PI3K/AKT/mTOR pathway, a signalling network involved in cancer cell growth, survival and treatment resistance. The PI3K pathway is one of the most frequently altered pathways in breast cancer, particularly in HR-positive, HER2-negative disease. Approximately 70% of breast cancers are HR-positive, HER2-negative, and around 40% of these tumours contain PIK3CA mutations. Unlike therapies targeting individual components of the pathway, Celcuity’s approach is designed to inhibit multiple signalling nodes within the PAM pathway. Phase III VIKTORIA-1 Trial Supports FDA Approval The FDA approval was supported by data from the Phase III VIKTORIA-1 trial, which evaluated Revtorpyk in patients with advanced HR-positive, HER2-negative breast cancer. The study enrolled 701 patients across both: PIK3CA-mutant tumours PIK3CA wild-type tumours Participants were randomised to receive: Revtorpyk plus fulvestrant and Ibrance Revtorpyk plus fulvestrant Fulvestrant alone Both patient populations met the trial’s primary endpoint of progression-free survival (PFS). The FDA submission focused initially on the PIK3CA wild-type population, which received priority review earlier this year. Revtorpyk Demonstrated Progression-Free Survival Benefit in Wild-Type Breast Cancer In the PIK3CA wild-type cohort, Celcuity reported significant improvements with Revtorpyk-based treatment combinations. The triplet combination of: Revtorpyk Fulvestrant Ibrance reduced the risk of disease progression compared with fulvestrant alone. Key results included: Treatment Median Progression-Free Survival Revtorpyk + fulvestrant + Ibrance 9.3 months Fulvestrant alone 2 months This represented a 76% improvement in progression-free survival compared with fulvestrant monotherapy. The Revtorpyk and fulvestrant combination also demonstrated statistically significant benefit, achieving a median PFS of 7.4 months. Objective response rates were: 32% for Revtorpyk + fulvestrant + Ibrance 28% for Revtorpyk + fulvestrant 1% for fulvestrant alone Additional Opportunity in PIK3CA-Mutated Breast Cancer Celcuity is also pursuing a potential expansion into PIK3CA-mutated breast cancer, where Revtorpyk demonstrated positive results in the VIKTORIA-1 trial. In this patient group, the comparator was: Novartis’ PI3Kα inhibitor Piqray (alpelisib) plus fulvestrant Presented data showed: Revtorpyk triplet therapy reduced the risk of disease progression or death by 50% Revtorpyk plus fulvestrant reduced the risk by 49% Median progression-free survival was: Treatment Median PFS Revtorpyk + fulvestrant + Ibrance 11.1 months Revtorpyk + fulvestrant 11.3 months Piqray + fulvestrant 5.6 months Celcuity announced plans to submit a supplemental regulatory application based on these findings. Challenges Remain Around Intravenous Delivery Despite positive clinical results, questions remain around how Revtorpyk will compete in a treatment landscape increasingly focused on convenience and patient quality of life. Unlike many modern targeted therapies that are administered orally, Revtorpyk requires intravenous delivery. Some clinicians have highlighted this as a potential limitation, particularly in a disease setting where patients may prefer treatments that reduce hospital visits. Denise Yardley, associate director of breast cancer research at Sarah Cannon Research Institute, noted that while Revtorpyk appeared more effective than Piqray, intravenous administration could create challenges for adoption. She also highlighted that PI3K-targeting therapies can be difficult to use due to side effects including: Rash Diarrhoea Hyperglycaemia The Future of PI3K-Targeted Breast Cancer Treatment Revtorpyk enters a competitive breast cancer market where pharmaceutical companies continue to develop increasingly targeted approaches based on tumour biology. The approval reinforces the importance of pathway-based therapies in HR-positive, HER2-negative breast cancer, particularly for patients whose tumours do not contain traditional actionable mutations. For Celcuity, future success will depend on balancing clinical benefit with practical considerations such as administration burden, tolerability and positioning against established targeted therapies. Summary The FDA has approved Celcuity’s Revtorpyk (gedatolisib) for adults with HR-positive, HER2-negative advanced breast cancer without PIK3CA mutations. Supported by Phase III VIKTORIA-1 data, the therapy demonstrated improved progression-free survival when combined with fulvestrant, with or without Ibrance. While the approval expands treatment options for patients with limited alternatives, Celcuity will need to overcome challenges around intravenous delivery and the broader tolerability concerns associated with PI3K-targeting therapies as it seeks commercial adoption. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Sacituzumab tirumotecan plus Keytruda improves progression-free survival in advanced NSCLC, expanding potential role of ADC-immunotherapy combinations. Kelun-Biotech’s antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), in combination with Merck & Co.’s Keytruda (pembrolizumab), has achieved a late-stage clinical success in first-line non-small-cell lung cancer (NSCLC), strengthening the potential of ADC-immunotherapy combinations across a broader patient population. The Phase III OptiTROP-Lung06 trial met its primary endpoint, demonstrating that sac-TMT plus Keytruda delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with Keytruda combined with standard chemotherapy in patients with locally advanced or metastatic NSCLC. The positive results focus specifically on patients with PD-L1 tumour proportion scores below 1% — a population with limited response to existing immunotherapy approaches. Expanding Treatment Options in PD-L1-Negative NSCLC The OptiTROP-Lung06 study enrolled 432 patients with previously untreated locally advanced or metastatic NSCLC whose tumours had PD-L1 expression levels below 1%. Patients were randomised to receive either: Sacituzumab tirumotecan plus Keytruda Keytruda plus pemetrexed and platinum-based chemotherapy The study’s primary endpoint was progression-free survival assessed by blinded independent central review (BICR). Top-line results showed the ADC combination achieved a significant improvement in PFS compared with the chemotherapy-based regimen. The combination also demonstrated a positive trend in overall survival, although further follow-up will be required to determine the full impact. Kelun reported that the safety profile remained consistent with previous studies, with no new safety concerns identified. The company plans to discuss the results with Chinese regulatory authorities. Merck’s Strategic Bet on Sac-TMT The latest results reinforce Merck’s growing investment in sac-TMT, following its agreement with Kelun-Biotech in 2022 for exclusive rights outside China. Under the partnership, Merck gained global development and commercialisation rights for the TROP2-targeting ADC, while Kelun continues to develop the asset in China. Sac-TMT, marketed as Jia Tai Lai in China, has already received approval in four indications, including: Triple-negative breast cancer EGFR mutation-positive NSCLC HR-positive/HER2-negative breast cancer The ADC is now being evaluated across multiple tumour types as Merck looks to expand its oncology pipeline ahead of future market challenges. Building Momentum Across Lung Cancer Studies The OptiTROP-Lung06 success follows another Phase III win for the combination in first-line NSCLC. In the OptiTROP-Lung05 trial, sac-TMT plus Keytruda demonstrated improved PFS compared with Keytruda alone in treatment-naïve patients with PD-L1-positive NSCLC. Additional data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed the combination reduced the risk of disease progression or death by 65% compared with Keytruda monotherapy after a median follow-up of 10.5 months. Together, the results suggest sac-TMT could have potential across a wide range of NSCLC patients, regardless of PD-L1 status. Kelun CEO Michael GE said the combined findings from OptiTROP-Lung05 and OptiTROP-Lung06 highlight the “strong synergetic effect” of sac-TMT combined with Keytruda and support its potential to benefit the broader first-line NSCLC population. The Growing Role of ADCs in Oncology ADC technology has become one of the most competitive areas in oncology development, combining the targeting ability of antibodies with the cancer-killing effects of cytotoxic payloads. By selectively delivering therapy to tumour cells, ADCs aim to improve efficacy while reducing systemic toxicity compared with traditional chemotherapy. Sac-TMT is currently being investigated in 10 registrational lung cancer studies, including five trials in China and five global studies. Beyond lung cancer, the ADC has also achieved a late-stage success in endometrial cancer and forms part of Merck’s wider TroFuse Phase III programme evaluating ADC-based combinations across multiple tumour types. What This Means for the NSCLC Market The latest Phase III success adds further momentum to the shift towards combination approaches in lung cancer treatment. While PD-1 inhibitors such as Keytruda have transformed NSCLC care, many patients — particularly those with low or absent PD-L1 expression — continue to require more effective treatment options. If future regulatory submissions are successful, sac-TMT plus Keytruda could strengthen Merck’s position in a highly competitive lung cancer market while demonstrating the expanding role of ADCs beyond traditional chemotherapy-based treatment pathways. For pharmaceutical companies, the result also highlights the growing importance of strategic partnerships with biotech innovators as major players look to build next-generation oncology portfolios. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Acquisition adds FDA-authorised fibromyalgia therapy and strengthens smartphone-based digital health offering XRHealth has acquired Swing Therapeutics, expanding its digital therapeutics portfolio beyond virtual reality and into smartphone-based care for chronic pain and fibromyalgia. The acquisition brings together XRHealth's extended reality (XR) therapies with Swing's FDA-authorised digital therapeutic, Stanza, and its virtual chronic pain management platform, creating a broader digital care ecosystem for patients living with long-term pain conditions. The deal also reflects a wider trend across digital health, where companies are combining software, connected devices and virtual clinical services to deliver more scalable healthcare outside traditional clinical settings. XRHealth broadens digital therapeutics portfolio XRHealth has built its business around immersive therapeutic technologies, including virtual reality (VR) programmes used to support pain management, mental health and cognitive rehabilitation. Its flagship FDA-registered VR platform is prescribed as Durable Medical Equipment (DME), allowing patients to receive clinician-guided therapy remotely. With the acquisition of Swing Therapeutics, XRHealth is expanding beyond immersive technologies into smartphone applications, wearable devices and connected digital care. The combined platform now supports patients through multiple digital treatment modalities depending on clinical need. Stanza becomes part of XRHealth's chronic pain offering A key asset in the acquisition is Stanza, the first FDA-authorised digital behavioural therapy specifically indicated for fibromyalgia symptoms. Delivered through a smartphone application, Stanza is designed to help patients manage chronic pain using evidence-based behavioural interventions without requiring medication or invasive procedures. The therapy was evaluated in a Phase III randomised controlled trial published in The Lancet, where patients demonstrated significant improvements across multiple clinical outcomes, including: Fibromyalgia symptom severity Pain intensity Fatigue Sleep quality Depression The programme is delivered through Swing Care, a virtual clinic that combines digital therapy with clinician oversight, medication management, mental health support and personalised coaching. According to the company, thousands of patients have already received treatment through the platform. Virtual care model delivers long-term support Swing Care extends beyond digital therapy by integrating licensed clinicians into the treatment pathway. Reported one-year outcomes showed: 88% of patients experienced improvements in overall wellbeing 50.2% reported feeling "much improved" or better after treatment Following the acquisition, XRHealth plans to incorporate these services into its existing network of virtual clinics using its established reimbursement model. The combined platform aims to offer patients a more comprehensive approach to chronic pain management while improving access to specialist care. Digital health consolidation continues The Swing acquisition continues XRHealth's strategy of building an integrated digital healthcare platform through targeted acquisitions. Recent deals include: RealizedCare (2025) – adding chronic pain and behavioural health programmes alongside AI-supported patient triage. Innerworld – bringing avatar-based virtual mental health communities. NeuroReality (2024) – expanding neurological rehabilitation capabilities. Amelia Virtual Care (2023) – strengthening immersive therapeutic technologies. Each acquisition has expanded XRHealth's ability to deliver remote care across physical, cognitive and behavioural health conditions. Meeting growing demand for scalable chronic pain care Chronic pain remains one of healthcare's largest unmet needs, placing significant pressure on healthcare systems facing clinician shortages and rising patient demand. Digital therapeutics are increasingly viewed as one solution to improving access while reducing the reliance on in-person appointments. By combining virtual reality therapy, smartphone-based digital therapeutics, wearable technologies and clinician-led virtual care, XRHealth is positioning itself as a broader digital health platform capable of supporting patients across multiple treatment settings. What the acquisition means The acquisition demonstrates how the digital therapeutics market is evolving beyond single technologies towards integrated care platforms. Rather than focusing solely on virtual reality, XRHealth now combines immersive therapies, mobile applications and virtual clinical services under one ecosystem. As healthcare providers continue to adopt remote care models, platforms capable of delivering evidence-based treatment across multiple digital channels are expected to play an increasingly important role in chronic disease management, particularly in areas such as chronic pain, behavioural health and Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, marking the pharmaceutical giant's entry into the rapidly evolving psychedelic therapeutics market. The acquisition strengthens Lilly's neuroscience portfolio with a pipeline of late-stage psychedelic-based therapies aimed at treatment-resistant depression (TRD), major depressive disorder (MDD) and other difficult-to-treat psychiatric conditions. The transaction is expected to close during the third quarter of 2026. Lilly Expands Neuroscience Portfolio Through AtaiBeckley Acquisition Under the agreement, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, valuing the company at approximately $2.8 billion. Shareholders will also be eligible to receive a contingent value right (CVR) worth $2.50 per share, representing around $1 billion in additional milestone payments linked to the clinical and regulatory progress of the company's lead psychedelic programmes. The acquisition follows months of industry speculation that Lilly was evaluating opportunities within the psychedelic medicine sector. BPL-003 Leads AtaiBeckley's Psychedelic Pipeline The centrepiece of the acquisition is BPL-003, an intranasal formulation of mebufotenin benzoate currently being developed for treatment-resistant depression. The therapy recently achieved both primary and secondary endpoints in a Phase IIb clinical trial, with a global Phase III programme already underway. Lilly will also acquire VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT), which is expected to enter late-stage clinical development for major depressive disorder. A third pipeline candidate, EMP-01, is an oral formulation of R-MDMA being investigated as a treatment for social anxiety disorder. Together, the portfolio provides Lilly with multiple late-stage assets targeting significant unmet needs across psychiatry. Psychedelic Medicines Continue to Gain Pharmaceutical Momentum The acquisition reflects growing pharmaceutical confidence in psychedelic-based medicines as a new generation of treatments for neuropsychiatric disorders. Interest in the sector has accelerated following the commercial success of Johnson & Johnson's Spravato (esketamine), while several other companies continue advancing psychedelic therapies through late-stage development. Industry momentum has also been supported by regulatory initiatives designed to accelerate the development of innovative treatments for severe mental health conditions. Why the Deal Matters Treatment-resistant depression remains one of the largest unmet needs in mental healthcare, with many patients failing to respond adequately to conventional antidepressants. Rapid-acting psychedelic therapies are being investigated as potential alternatives capable of producing faster and more durable clinical responses through novel mechanisms of action. By acquiring AtaiBeckley, Lilly gains immediate access to a differentiated pipeline without the lengthy timelines associated with early-stage drug discovery. The transaction also expands Lilly's position in neuroscience beyond traditional psychiatric medicines into one of the fastest-growing areas of pharmaceutical innovation. Executive Commentary Lilly Neuroscience President Carole Ho said the acquisition reflects the company's commitment to addressing difficult-to-treat mental health conditions. "Treatment-resistant depression persists even after multiple treatments have failed. Advancing AtaiBeckley's investigational therapies gives us a real chance to change that." Analysts have also highlighted the strategic importance of the acquisition, noting that the deal broadens Lilly's neuroscience portfolio while positioning the company at the forefront of next-generation psychiatric drug development. Outlook The acquisition represents another significant vote of confidence in psychedelic therapeutics from a major pharmaceutical company. With BPL-003 already entering Phase III development and additional candidates progressing towards late-stage studies, Lilly is positioning itself to become a major player in the future treatment landscape for depression and other serious psychiatric disorders. As clinical evidence continues to mature, the deal highlights how large pharmaceutical companies are increasingly turning to innovative neuroscience platforms to address some of the most challenging areas of medicine. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market. Merck & Co. (MSD) has secured US Food and Drug Administration (FDA) approval for Lipfendra (enlicitide), making it the first once-daily oral PCSK9 inhibitor approved in the US for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH). The approval marks a significant milestone in the cholesterol treatment landscape, introducing an oral alternative to injectable PCSK9 inhibitors that have transformed LDL-C management over the past decade. First Oral PCSK9 Inhibitor Approved in the US Lipfendra is indicated for adults with hypercholesterolaemia, including patients with HeFH, and works by inhibiting PCSK9, a protein involved in regulating LDL cholesterol levels. Unlike existing PCSK9 therapies, which require injections every two weeks or monthly, Lipfendra is administered as a once-daily tablet, potentially offering greater convenience for patients and expanding access to this class of cholesterol-lowering medicines. Dean Y. Li, President of Merck Research Laboratories, described the approval as a pivotal moment, saying the drug provides patients with an important new treatment option. Phase III Trials Demonstrated Significant LDL-C Reduction The FDA approval was supported by data from two Phase III clinical trials: CORALreef Lipids CORALreef HeFH In the CORALreef HeFH study, Lipfendra achieved approximately 59% LDL-C reduction versus placebo in patients with heterozygous familial hypercholesterolaemia. Meanwhile, the CORALreef Lipids trial demonstrated an almost 56% reduction in LDL-C among patients with atherosclerotic cardiovascular disease (ASCVD). Merck is also conducting a cardiovascular outcomes study to determine whether LDL-C reductions translate into lower rates of heart attacks, strokes and cardiovascular death. Challenging the Injectable PCSK9 Market The PCSK9 inhibitor market has traditionally been dominated by injectable biologics, including: Amgen's Repatha (evolocumab) Sanofi and Regeneron's Praluent (alirocumab) While these medicines have demonstrated strong efficacy, injectable administration has been viewed as a barrier for some patients. Lipfendra's oral formulation could broaden use of PCSK9 inhibition, particularly within primary care settings where physicians may favour a tablet over injectable therapy. Pricing also appears central to Merck's commercial strategy. Lipfendra will launch with a list price of approximately $315 per month, substantially below the typical $500–600 monthly cost of existing injectable PCSK9 inhibitors. Analysts believe this pricing strategy could accelerate adoption and expand the overall market rather than simply compete for existing patients. Strategic Importance for Merck Lipfendra represents one of Merck's most important late-stage pipeline assets as the company prepares for the eventual loss of exclusivity of blockbuster immunotherapy Keytruda (pembrolizumab) in 2028. The company has identified several pipeline medicines expected to drive future growth, with Lipfendra viewed as a potential multi-billion-dollar product. Analysts suggest that widespread uptake among primary care physicians could generate peak annual sales approaching $5bn, particularly if oral therapy encourages earlier use of PCSK9 inhibition in cholesterol management. Competition Continues to Build Although Lipfendra is the first oral PCSK9 inhibitor to reach the market, competition is already emerging. AstraZeneca is developing AZD0780, an investigational oral PCSK9 inhibitor that has demonstrated nearly 51% LDL-C reduction in mid-stage studies. One potential differentiator may be dosing convenience. Lipfendra must be taken on an empty stomach, with patients required to wait at least 30 minutes before eating, while AstraZeneca's candidate has not demonstrated the same fasting requirement. As oral PCSK9 therapies enter clinical practice, convenience, pricing and long-term cardiovascular outcomes are likely to become key differentiators. Outlook The approval of Lipfendra introduces the first oral PCSK9 inhibitor into clinical practice and could reshape the treatment landscape for patients requiring intensive LDL-C lowering. By combining efficacy comparable to injectable therapies with oral administration and competitive pricing, Merck is positioning Lipfendra to expand adoption of PCSK9 inhibition beyond specialist care. With cardiovascular outcomes data still to come and additional oral competitors in development, the approval represents the beginning of a new phase in cholesterol management rather than the end of the story. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The Series B financing gives Crystalys additional capital to progress its late-stage clinical programme and prepare dotinurad for potential commercialisation. Crystalys Therapeutics has closed an oversubscribed $130 million Series B financing led by Frazier Life Sciences to support the global late-stage development and commercialisation preparation of dotinurad for gout. The investment extends support for two registration-directed Phase 3 trials and a Phase 2 study as the company works towards further clinical, regulatory and commercial-readiness milestones. Field Content Alert Type Deal Companies Crystalys Therapeutics; financing led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund and existing investors. Deal Type Series B financing Asset or Company Crystalys Therapeutics and its lead candidate, dotinurad Therapy Area(s) Rheumatology; gout Technology or Modality Once-daily oral URAT1 inhibitor Deal Value $130 million in closed Series B financing. Development Stage Phase 3, with two registration-directed studies underway; an additional Phase 2 study is also ongoing. Geography Global clinical development and commercialisation preparation What Happened Crystalys closed an oversubscribed $130 million Series B round led by Frazier Life Sciences. The proceeds will support the RUBY and TOPAZ Phase 3 trials, the Phase 2 AMETHYST study, commercialisation preparation and the company’s operational runway through anticipated clinical and regulatory milestones. Why It Matters The financing provides Crystalys with additional resources to progress dotinurad across a broad gout-development programme while preparing the company for potential regulatory submissions and commercialisation. It also supports continued development of a possible second-line option for patients inadequately served by existing urate-lowering treatments. Supporting Context Dotinurad is already approved in Japan, China, the Philippines, Taiwan and Thailand. Crystalys is developing it as a potential second-line therapy intended to reduce uric acid, gout flares and tophi. Key Takeaway The $130 million financing gives Crystalys further runway to move dotinurad through late-stage development and towards commercial readiness. What to Watch Results from the RUBY, TOPAZ and AMETHYST studies and any subsequent clinical, regulatory or commercialisation milestones. Primary Source Crystalys Therapeutics’ official financing announcement Relevant Date 22 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Examining the impact of dermatology education on knowledge application and patient care quality. Dermatology education must address a broad spectrum of conditions, from chronic inflammatory diseases to complex diagnostic challenges. nuaxia analysed behavioural data from dermatology-focused medical education activities to evaluate how effectively these programmes support healthcare professional learning. By assessing changes in knowledge and competence following educational interventions, this analysis offers objective insights into the value of dermatology education and its role in improving clinical understanding. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 79% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 79% improved 19% remained stable Only 2% saw a decrease This highlights how education programmes can support HCPs’ growth, regardless of their initial level of knowledge or experience. 44% Achieved the Top Score After Medical Education Activity 44% of participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (51.6%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (43.5%) or High (40.4%) categories. The results underscore that medical education’s true value lies in its ability to change behaviour and outcomes, not just impart information. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This advancement for HCPs directly contributes to better healthcare outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Assessing cardiology training programmes and their role in improving professional competency. Cardiology remains one of the most data-intensive and guideline-driven therapy areas, making high-quality education essential. To assess the effectiveness of cardiology education, nuaxia analysed behavioural data from cardiology-focused learning activities. This analysis evaluates changes in healthcare professionals' knowledge and competence before and after educational interventions, providing clear evidence of how cardiology education supports learning and clinical confidence. Key Findings at a Glance 90% of Participants Improved Their Scores 90% of HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 47% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 47% improved 45% remained stable Only 8% saw a decrease This shift underlines how well-structured education meets HCPs where they are and helps them grow, regardless of the starting point. 30% Achieved the Top Score After Medical Education Activity Importantly, 30% of participants progressed to the top performance group, demonstrating that CME activities are driving measurable improvements in HCP knowledge and competence. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.0%) or Average (27.5%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (50.0%) or Top (30.0%) categories. This demonstrates that medical education’s power lies not just in teaching, but in transforming practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change This benefits not only HCPs but ultimately improves patient outcomes on a global scale. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Evaluating the effectiveness of endocrinology learning interventions to support better clinical practice. Endocrinology requires ongoing education to keep pace with evolving treatment guidelines and long-term disease management strategies. But how effective is endocrinology-focused education in driving meaningful learning outcomes? nuaxia analysed behavioural data from endocrinology education activities to answer this question. Through detailed pre- and post-education analysis, nuaxia assessed changes in knowledge and competence, providing data-backed insights into the real-world impact of endocrinology education programmes. Key Findings at a Glance 87% of Participants Improved Their Scores Nearly nine out of ten participants showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 63% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 63% improved 25% remained stable Only 12% saw a decrease These insights show that personalised, structured education enables HCPs to progress meaningfully from any starting point. 32% Achieved the Top Score After Medical Education Activity Nearly a third of participants reached the top performance group, highlighting the effectiveness of CME activities in supporting HCP learning. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (42.7%) or High (42.7%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (46.5%) or Top (32.0%) categories. This shows that impactful medical education doesn’t just inform - it transforms. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The benefits reach far beyond learners, fostering measurable improvements in global patient care. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Insights into oncology learning programmes and their impact on clinical practice and patient care. Oncology is one of the most complex and rapidly advancing areas of medicine, demanding continuous learning from healthcare professionals. But how effective is oncology education in keeping pace with this change? nuaxia analysed extensive behavioural data from oncology-focused educational activities to evaluate how learning interventions support knowledge and competence development. Through sophisticated data science methods, nuaxia measured changes in learning outcomes across oncology education programmes. This analysis provides evidence-based insights into the effectiveness of oncology education, highlighting its role in supporting informed clinical decision-making. Key Findings at a Glance 92% of Participants Improved Their Scores With 92% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 70% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 70% improved 26% remained stable Only 4% saw a decrease These findings highlight how well-designed CME meets learners where they are and guides them toward higher competence. 33% Achieved the Top Score After Medical Education Activity Importantly, a third of participants progressed to the top performance group, highlighting the role of CME in enabling HCPs to achieve higher levels of performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the Average (45.7%) or High (33.9%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (48.5%) or Top (32.7%) categories. The data confirms that meaningful education in healthcare doesn’t just inform, it shapes practice. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change The impact extends beyond healthcare professionals, enhancing care for patients around the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Key findings from neurology education activities and their influence on learning outcomes. Neurology presents unique educational challenges, with intricate disease pathways and rapidly expanding treatment options. To understand how education supports learning in this area, nuaxia analysed behavioural data from neurology-focused medical education activities. This analysis examines changes in knowledge and competence among healthcare professionals, using objective data to uncover how neurology education influences learning outcomes and supports more confident clinical practice. Key Findings at a Glance 97% of Participants Improved Their Scores Nearly all HCPs showed measurable improvements in knowledge and competence following the educational activities. This headline figure demonstrates the strong learning value embedded in our programmes. 71% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 71% improved 28% remained stable Only 1% saw a decrease This reflects how thoughtfully designed CME can meet HCPs where they begin and help them achieve their full potential. 48% Achieved the Top Score After Medical Education Activity Almost half of the participants reached the top performance group, showing that CME activities are effectively supporting HCPs in achieving high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.9%) or Average (38.8%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (48.2%) or High (44.2%) categories. This proves that impactful CME equips HCPs to move from knowledge to action. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change By supporting HCP development, these educational programmes drive positive change in patient outcomes across the globe. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Analysing how targeted haematology training enhances understanding and informs treatment decisions. Haematology education plays a vital role in supporting healthcare professionals managing complex and often life-threatening conditions. But how effective are current educational approaches in this field? nuaxia analysed behavioural data from haematology-focused education activities to evaluate their impact on learner knowledge and competence. Using data-driven methodologies, this analysis tracks changes in learning outcomes before and after educational interventions, providing robust evidence of how haematology education contributes to improved understanding and professional development. Key Findings at a Glance 93% of Participants Improved Their Scores With 93% of participants showing measurable improvements, these results demonstrate the clear impact of our educational programmes on HCP performance. 72% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 72% improved 23% remained stable Only 5% saw a decrease The results underline how effective education accommodates diverse learning levels and fosters ongoing growth. 36% Achieved the Top Score After Medical Education Activity Over a third of participants progressed to the top performance group, underscoring the measurable impact of CME on professional learning outcomes. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (41.5%) or Average (39.2%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.5%) or Top (36.6%) categories. These findings illustrate that education in medicine is not merely informative; it inspires measurable improvements. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These gains for HCPs ultimately translate into higher-quality care for patients worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com